This section captures essential identification details about the field representative and the healthcare practitioner to ensure proper attribution, compliance tracking, and relationship context. Accurate metadata is critical for audit trails and regulatory inspection readiness.
Field Representative Employee ID
Field Representative Full Name
Field Representative Official Email
Field Representative Direct Phone Number
Field Representative Geographic Region
North America
Europe
Asia-Pacific
Latin America
Middle East/Africa
Global
Date and Time of Interaction with Healthcare Practitioner
Interaction Setting/Context
In-person office visit
Hospital/clinic corridor
Scheduled virtual meeting
Phone call
Medical conference
Scientific symposium
Dinner meeting
Other professional event
Healthcare Practitioner Full Name
Healthcare Practitioner Primary Credential
Medical Doctor (MD)
Doctor of Osteopathic Medicine (DO)
Nurse Practitioner (NP)
Physician Assistant (PA)
Doctor of Pharmacy (PharmD)
Registered Nurse (RN)
Other licensed prescriber
Healthcare Practitioner Medical Specialty/Area of Practice
Healthcare Practitioner Institution/Practice Name
Institution Type
Academic Medical Center
Community Hospital
Private Practice
Hospital System/Network
Government/Public Hospital
Specialty Clinic
Research Institution
Other
Institution Country
Institution State/Province
Institution City
Duration of Professional Relationship with this Healthcare Practitioner
Less than 6 months
6-12 months
1-2 years
2-5 years
More than 5 years
First-time interaction
Estimated Number of Previous Interactions with this Healthcare Practitioner
Date of Most Recent Prior Interaction (if applicable)
Has this Healthcare Practitioner previously asked off-label questions about our products?
This section documents the specific pharmaceutical product and the precise nature of the clinical inquiry. Accurate and detailed capture of the question is essential for medical affairs to provide scientifically accurate, compliant, and clinically relevant responses. Include all relevant clinical context that may impact the response.
Product Brand Name (if applicable)
Product Generic/Scientific Name
Product Strength/Formulation
Product's Currently Approved Indication(s) in this Country (select all that apply)
Oncology indication
Cardiovascular indication
Infectious disease indication
Metabolic/Endocrine indication
Neurological indication
Respiratory indication
Autoimmune indication
Hematological indication
Other therapeutic area
Not yet approved/Investigational
Nature of the Clinical Inquiry
Off-label use for unapproved indication
Off-label use for unapproved patient population
Off-label dosing or administration
Off-label combination therapy
Safety concern for off-label use
Efficacy question for off-label use
Mechanism of action question
Pharmacokinetic/pharmacodynamic question
Drug-drug interaction question
Comparative effectiveness question
Health economics/outcomes research question
Other scientific inquiry
Specific Off-Label Indication or Clinical Scenario Being Discussed (if applicable)
Verbatim Clinical Question as Stated by Healthcare Practitioner
Did the Healthcare Practitioner provide specific patient case details?
Type of Clinical Information Requested (select all that apply)
Clinical trial data
Real-world evidence
Safety data
Dosing recommendations
Mechanism of action explanation
Drug interaction potential
Contraindications
Pharmacokinetic data
Patient selection criteria
Comparative efficacy
Health economic data
Regulatory status
Publication references
Expert opinion/consensus
Other
Did the Healthcare Practitioner reference specific clinical studies, publications, or data sources?
Is this inquiry related to a pediatric, pregnant, or lactating patient population?
Additional Clinical Context or Background Information Relevant to the Inquiry
This critical section documents the unsolicited nature of the request and verifies compliance with company policies and regulatory requirements. Off-label information may only be provided in response to unsolicited requests. Any indication that the question was prompted or solicited by the field representative must be immediately escalated. Complete this section with utmost accuracy.
CONFIRMATION: Was this clinical inquiry completely unsolicited and initiated solely by the Healthcare Practitioner?
How did the Clinical Inquiry Arise? (Select the most appropriate description)
Spontaneously during general discussion
Directly following on-label information discussion
During review of patient case
In response to HCP viewing promotional materials
During HCP-initiated literature discussion
At conclusion of formal presentation
During question-and-answer session
Other HCP-initiated scenario
Did you discuss the product's approved indication(s) with the Healthcare Practitioner BEFORE the off-label question was asked?
Did you proactively mention, suggest, or allude to any off-label uses of the product?
Did you provide any promotional materials (visual aids, brochures, leave-behinds) during this interaction?
Did you make any promises or commitments regarding specific answers, timelines, or outcomes to the Healthcare Practitioner?
Did you reference any internal, confidential, or unpublished data during the discussion?
Provide a Detailed Narrative of the Conversation Flow Leading to the Clinical Inquiry
I attest that this clinical inquiry was entirely unsolicited, initiated by the Healthcare Practitioner without any prompting, suggestion, or encouragement from me. I have accurately documented the interaction to the best of my ability and understand that any misrepresentation may result in disciplinary action.
I confirm that I did not proactively share any off-label information, make any inappropriate promises, or provide promotional materials specifically about off-label uses.
This section enables appropriate triage and resource allocation by medical affairs. Accurate urgency assessment ensures patient safety concerns are addressed immediately while routine inquiries receive appropriate attention. Specify communication preferences to facilitate effective knowledge transfer.
Urgency Level Assessment
CRITICAL - Immediate patient safety risk
HIGH - Urgent clinical decision needed within 24-48 hours
MEDIUM - Important clinical question within 1 week
LOW - General information request within standard timeline
Rationale for Urgency Assessment
Does this inquiry involve a potential serious adverse event or product safety concern?
Is there an active patient waiting for treatment decision based on this information?
Healthcare Practitioner's Preferred Response Method
Direct telephone call from Medical Affairs
Formal written medical response letter
Email summary with scientific references
Peer-to-peer discussion with Medical Director
Scientific publication reprints
Virtual meeting with clinical scientist
No specific preference
Should Medical Affairs communicate directly with the Healthcare Practitioner or through the Field Representative?
Direct communication with HCP is appropriate
All communication should be channeled through me
HCP prefers field rep to coordinate
Depends on complexity of response
Healthcare Practitioner Preferred Contact Information for Response
Healthcare Practitioner Availability for Follow-up Discussion (if applicable)
Will additional stakeholders need to be included in the response?
Healthcare Practitioner's Requested Response Date (if specified)
Additional Context to Support Appropriate Response Delivery
This final section captures the field representative's assessment to guide internal medical affairs handling. Your input helps ensure appropriate reviewer assignment, priority setting, and identification of potential issues requiring escalation to specialized teams or leadership.
Field Representative Recommended Priority for Medical Affairs Review
Immediate review required (< 24 hours)
Urgent review (1-2 business days)
Standard priority (3-5 business days)
Routine review (5-10 business days)
Informational only (no immediate action needed)
Recommended Medical Affairs Reviewer Specialty
Medical Director - Therapeutic Area
Clinical Scientist - Research & Development
Drug Safety & Pharmacovigilance
Regulatory Affairs Specialist
Health Economics & Outcomes Research
Medical Information Specialist
Global Medical Affairs Lead
Combination/Multidisciplinary review
Does this inquiry require escalation beyond standard medical affairs review?
Have we received similar unsolicited off-label inquiries from other Healthcare Practitioners recently?
Are there any attachments or supporting documents to include with this intake?
Field Representative Additional Notes for Medical Affairs Reviewer
Field Representative Digital Signature - Attesting to Accuracy and Compliance
Form Submission Timestamp
I have reviewed all information entered for accuracy and completeness. I understand that incomplete or inaccurate submissions may delay the medical affairs response and could compromise compliance. I have reported any safety concerns through appropriate channels and have not included any patient-identifiable information in this form.